AI Consensus Investment Thesis
Eli Lilly and (LLY) Stock Forecast and AI Rating
Forecast targets and rating
Final recommendation
NEUTRAL
Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.
1-Year
BUY$1,244
+7.9%+8.6% incl. dividends5-Year
NEUTRAL$1,630
+41.4%+45.7% incl. dividendsLatest flagship insight
Metabolic Volume Scaling Converts Surging Demand Into Massive Cash Generation
There is high consensus that surging cardiometabolic prescription volume and oral small-molecule adoption will double operational earnings over five years. However, sharp divergence exists regarding valuation durability, as persistent gross-to-net price erosion and elevated bond yields enforce mechanical multiple compression.
This is the latest published deep-analysis batch. Audit published forecasts in full transparency
Warren Buffett (Value Purist), J.P. Morgan (Titan), Michael Burry (Vulture), Sherlock Holmes (Whistleblower), Superintelligence (Anthropologist), Universal Investor (Polymath), Ray Dalio (Strategist), Elon Musk (Visionary), Machiavelli (Insider). Some archetypes run in multiple modes, resulting in 14 advisors total.
Gemini
Claude
ChatGPTExecutive Summary
Dotted terms open concise definitions. Browse technical terms
If you invested $10,000 in Eli Lilly and at the forecast anchor (2026-09-18): $14,569 in five years versus $13,892 for S&P 500 benchmark.
* Return is calculated incl. 0.6% net dividend yield for Eli Lilly and.
20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView tableClose table
Frozen forecast from 18 Sept 2026. Prices in USD; returns exclude dividends. Each quarter is compounded from the previous quarter.
Swipe the table horizontally to read every column.
| Quarter | Target (USD) | Quarter return | Total return | Forecast rationale |
|---|---|---|---|---|
| Q4 2026 | 1,176.95 | +2.08% | +2.08% | Robust third-quarter incretin volumes and early oral channel fill drive solid revenue growth, though elevated Treasury yields constrain multiple expansion. |
| Q1 2027 | 1,213.97 | +3.15% | +5.29% | Record full-year earnings confirm expanding operating cash flow, but conservative guidance highlights ongoing gross-to-net realized price concessions across commercial books. |
| Q2 2027 | 1,241.29 | +2.25% | +7.66% | Scaling small-molecule oral manufacturing lowers unit costs and expands margins, counterbalancing the implementation of statutory government price demonstration models. |
| Q3 2027 | 1,244.13 | +0.23% | +7.91% | Mid-year formulary rebate renegotiations induce temporary gross-to-net margin compression, keeping equity price appreciation subdued despite rising patient script counts. |
| Q4 2027 | 1,278.22 | +2.74% | +10.87% | Pivotal regulatory submissions for triple-agonist retatrutide and expanded cardiometabolic comorbidity indications re-energize forward earnings visibility and institutional accumulation. |
| Q1 2028 | 1,310.97 | +2.56% | +13.71% | Full-year results highlight surging free cash conversion as prior manufacturing builds achieve operational validation, funding expanded share repurchases. |
| Q2 2028 | 1,339.92 | +2.21% | +16.22% | Initial commercial launch preparations for retatrutide offset headline noise from competitor trial readouts, preserving steady underlying operating profit growth. |
| Q3 2028 | 1,349.41 | +0.71% | +17.04% | Election-year drug pricing rhetoric and Medicare negotiation announcements create sector multiple drag, temporarily masking double-digit international volume gains. |
| Q4 2028 | 1,390.88 | +3.07% | +20.64% | Broadened commercial reimbursement for obesity-related heart failure and sleep apnea drives high-margin volume, supporting a constructive year-end equity advance. |
| Q1 2029 | 1,415.22 | +1.75% | +22.75% | Annual financial disclosures demonstrate operating income surpassing fifty billion dollars, with oral formulations capturing substantial primary-care and emerging-market share. |
| Q2 2029 | 1,439.25 | +1.70% | +24.83% | Challenger entries in oral and dual-agonist categories prompt selective commercial discounting, moderating quarterly profit growth to low single digits. |
| Q3 2029 | 1,446.75 | +0.52% | +25.48% | Manufacturing efficiencies across automated production campuses widen gross margins, absorbing domestic price erosion and generating solid sequential cash earnings. |
| Q4 2029 | 1,480.50 | +2.33% | +28.41% | Sustained free cash flow generation enables accelerated debt retirement and share repurchases, reinforcing per-share intrinsic value despite broader macro deceleration. |
| Q1 2030 | 1,503.02 | +1.52% | +30.37% | Publication of statutory Medicare Maximum Fair Price schedules enforces structural price adjustments, curbing multiple expansion while baseline volumes remain resilient. |
| Q2 2030 | 1,530.73 | +1.84% | +32.77% | International sales expansion across Asia and Latin America compensates for domestic pricing friction, maintaining steady operating cash-flow generation. |
| Q3 2030 | 1,536.63 | +0.39% | +33.28% | Maturing incretin market penetration shifts institutional focus toward defensive cash harvesting, resulting in modest, earnings-backed quarterly equity appreciation. |
| Q4 2030 | 1,570.72 | +2.22% | +36.24% | Advancements in next-generation amylin and neurodegenerative pipelines extend the intellectual property runway, supporting terminal valuation multiples into year-end. |
| Q1 2031 | 1,589.21 | +1.18% | +37.84% | Fiscal 2030 results validate over thirty-five billion dollars in distributable free cash flow, translating business compounding into steady share gains. |
| Q2 2031 | 1,608.75 | +1.23% | +39.54% | Stable chronic refill demand insulates operations from late-cycle economic headwinds, though early biosimilar preparation headlines restrict multiple re-expansion. |
| Q3 2031 | 1,630.20 | +1.33% | +41.40% | The five-year forecast culminates with the enterprise operating as a mature global cash generator, cementing durable low-double-digit compounding returns. |
The base-case investment thesis resolves around a powerful economic tension: unprecedented volumetric expansion across metabolic franchises versus persistent valuation multiplevaluation multipleA ratio comparing market or enterprise value with a financial measure such as earnings, revenue, book value, or cash flow.View full glossary entry compression. Surging prescription demand for injectable tirzepatide, combined with the primary-care rollout of oral orforglipron, drives revenue from eighty billion dollars toward one hundred thirty billion dollars. Because multi-billion-dollar manufacturing investments have crest commercial validation, operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry hold above forty-four percent, converting scale into immense free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry. Nonetheless, valuation multiples face systemic compression from thirty-nine times toward twenty-four times earnings under five percent benchmark yields and statutory drug price negotiations. Net earnings expansion comfortably outpaces multiple deflation, securing durable total returns.
Key insights
- Oral small-molecule commercialization decouples volume growth from complex injectable cold-chain logistics, unlocking primary-care demographics at structurally superior marginal production costs.
- Cresting manufacturing capital expenditurescapital expenditureCapital expenditure (CAPEX) is spending on long-lived assets or major improvements expected to support operations over multiple periods.View full glossary entry transition the corporate capital structurecapital structureThe mix of debt and equity used to finance a business.View full glossary entry from cash absorption into prolific free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry generation exceeding thirty billion dollars.
- Statutory Medicare negotiations and pharmacy benefit manager rebate widening enforce double-digit realized price erosion, establishing volume growth as the sole earnings driver.
The investment case centers on an unstoppable boom in demand for breakthrough diabetes and weight-loss treatments. As manufacturing bottlenecks disappear and an easy-to-take daily pill reaches global pharmacies, revenue and profits will surge. Even though governments and insurers are demanding steep discounts, and higher interest rates make high stock valuations harder to sustain, the sheer volume of new patients will easily overcome price cuts and deliver reliable long-term gains.
Key insights
- A convenient daily pill opens massive new patient markets without the hassle of weekly refrigerated injections.
- Massive factory construction is finishing, unlocking billions in spare cash for dividends and share repurchases.
- Mandatory government price cuts mean future profits must come entirely from selling more medicine at lower prices.
Deep Dive
Outside market consensus views the company as an unassailable biopharmaceutical monopoly destined for frictionless thirty-percent annual growth. Investors anchor on boundless global obesity demand, expecting oral therapies to simply stack on top of injectable sales without margin dilutiondilutionReduction in ownership percentage for existing shareholders caused by the issuance of new equity shares.View full glossary entry. The prevailing narrative assumes permanent pricing hegemony, blithely discounting sovereign reimbursement pushback and higher interest rates.
Paywalled preview begins: Deep Dive: detailed analysis
From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.
Deep Dive
Alpha Gap & Repricing Catalysts
Where does the current market narrative diverge from our AI Opinions—and what could close the gap?
Market Narrative
What does the market currently expect? Outside market consensus views the company as an unassailable biopharmaceutical monopoly destined for frictionless thirty-percent annual growth. Investors anchor on boundless global obesity demand, expecting oral therapies to simply stack on top of injectable sales without margin dilutiondilutionReduction in ownership percentage for existing shareholders caused by the issuance of new equity shares.View full glossary entry. The prevailing narrative assumes permanent pricing hegemony, blithely discounting sovereign reimbursement pushback and higher interest rates.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The crowd materially overestimates the permanence of peak gross pricing powerpricing powerThe ability of a company to raise prices without losing significant customer demand.View full glossary entry while underestimating the structural cash conversion of maturing manufacturing assets. External models focus on list prices, ignoring inevitable gross-to-net erosion from statutory Medicare caps and commercial pharmacy benefit manager rebates. However, the market simultaneously overlooks how oral small-molecule synthesis eliminates cold-chain capital intensitycapital intensityA business condition where large upfront spending on assets and infrastructure is needed to operate and grow.View full glossary entry, unlocking massive low-cost volume that generates superior free cash conversion.
Repricing Catalyst
What could make the market recognize and close that gap? Transparent net price disclosures in upcoming audited filings, coupled with initial commercial prescription data for oral orforglipron through 2027, will force a market repricing. Investors will directly observe that revenue growth is powered by explosive unit volume rather than pricing powerpricing powerThe ability of a company to raise prices without losing significant customer demand.View full glossary entry, compelling an orderly valuation multiplevaluation multipleA ratio comparing market or enterprise value with a financial measure such as earnings, revenue, book value, or cash flow.View full glossary entry compression alongside significant upward revisions in cash generation.
Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed / Fear
- Greed
- Volatility
- Moderate
- Cycle position
- Momentum
Most perspectives observe strong momentum driven by commercial adoption, yet disagree sharply on cycle maturity. Optimists view expansion as early-stage, whereas contrarians warn of an overshoot vulnerable to rapid multiple contraction as statutory price negotiations commence.
Macro Regime Fit
Does the current market environment support the thesis? The prevailing macroeconomic regimemacroeconomic regimeThe prevailing set of economic conditions including interest rates and inflation that influence asset pricing.View full glossary entry of restrictive monetary policy and ten-year Treasury yields hovering near five percent is a clear valuation headwind for high-multiple equities. However, cardiometabolic disease treatments exhibit virtually zero economic cyclicality; highly inelastic patient demand completely insulates core operating cash flows from broader stagflationary pressuresstagflationary pressuresEconomic pressures created when weak growth and persistent inflation occur together.View full glossary entry.
Advisor Disagreement
What do our AI Advisors disagree about most? The decisive analytical debate centers on valuation sensitivity and the trajectory of net price realization. Bullish perspectives argue that manufacturing debottlenecking, primary-care oral distribution, and label expansions into sleep apnea and heart failure will drive earnings growth that easily defends premium valuation multiples. Conversely, contrarians demonstrate that statutory Medicare price negotiations and commercial pharmacy benefit manager rebates will compress realized prices by low-to-mid-teens percentages annually. This disagreement will be resolved as quarterly SEC disclosures reveal whether gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry can hold above eighty-two percent as volume expands.
Base-Case Forces
Event Risk ScoreModerate47/100Near-certain positive forces
Top Drivers / Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Incretin franchise volume scaling | Competitive Positioning | +30% | +50% | Tirzepatide maintains undisputed clinical efficacy, converting diabetes and obesity treatment into chronic maintenance therapy. Expanding manufacturing capacity unlocks global commercial delivery, driving prescription volumes that easily overwhelm low-to-mid-teens gross-to-net realized price concessions and generating massive operational leverage. |
| Oral small molecule primary care expansion | Innovation And Product | +24% | +35% | Commercial rollout of oral orforglipron bypasses cold-chain logistics and autoinjector shortages, opening primary-care and emerging-market channels. Low chemical synthesis costs elevate gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry, accelerating cash conversion and dramatically broadening the treated patient pool beyond injectable cohorts. |
| Triple agonist clinical differentiation | Innovation And Product | +20% | +28% | Pivotal Phase 3 data for retatrutide demonstrating unprecedented weight reduction establishes an insurmountable clinical moat in severe metabolic disease. This clinical superiority protects premium formulary placement and insulates future corporate revenues against early-generation peptide generic erosiongeneric erosionThe loss of market share and revenue as patents expire and cheaper generic alternatives enter the market.View full glossary entry. |
| Manufacturing scale drives operating leverageoperating leverageThe sensitivity of operating profit to changes in revenue caused by the mix of fixed and variable costs.View full glossary entry | Operational Efficiency | +16% | +22% | Multi-billion-dollar domestic and international capital deployments are transitioning from cash-absorptive construction into operational production. Yield optimization and fixed-cost dilutiondilutionReduction in ownership percentage for existing shareholders caused by the issuance of new equity shares.View full glossary entry reduce unit production costs, expanding operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry toward forty-six percent and generating prolific free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry. |
Near-certain negative forces
Top Frictions / Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Valuation multiplevaluation multipleA ratio comparing market or enterprise value with a financial measure such as earnings, revenue, book value, or cash flow.View full glossary entry contraction under rate gravity | Macroeconomic And Macrofinancial | -18% | -3.0% | Persistent benchmark Treasury yields near five percent and restrictive monetary policy elevate equity discount rates. A trailing price-to-earnings multipleearnings multipleThe ratio of share price to earnings per share used to determine stock valuation.View full glossary entry of nearly thirty-nine times faces mechanical compression toward historical pharmaceutical averages of twenty-two to twenty-six times, dampening equity returns. |
| Statutory drug price negotiations and discounts | Regulatory | -16% | -20% | Implementation of Inflation Reduction Act mechanisms and mandatory statutory caps forces significant gross-to-net price concessions across government and commercial programs. This institutional price erosion constrains unit profitability, requiring relentless volume expansion merely to preserve margin health. |
| Competitive pipeline crowding and rebate warfare | Competitive Positioning | -12% | -15% | Rival combination therapies, next-generation oral incretins, and compounded peptide alternatives enter commercial channels. Pharmacy benefit managers leverage competing options to demand steeper formulary rebates, eroding pricing leverage and forcing defensive commercial marketing expenditures. |
| Heavy pipeline development and fixed depreciation | Capital Allocation | -9.0% | -11% | Capitalizing newly commissioned manufacturing facilities introduces substantial depreciation charges onto the income statement. Concurrently, recurring multi-billion-dollar acquired research and development outlays compete with shareholder distributions, keeping distributable cash flow below headline net income. |
What Could Break or Accelerate the Thesis
Plausible downside scenarios
Tail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Severe idiosyncratic class wide safety restriction | 16% | -34% | Emergence of a verified, severe adverse post-marketing safety signal—such as persistent gastrointestinal dysmotility or oncogenic pathology—could prompt FDA black-box warnings. Such intervention would trigger sudden patient discontinuations, severe product liability litigation, and a catastrophic derating of the core metabolic franchise valuation. |
| Radical mandatory statutory price parity decrees | 22% | -28% | Aggressive executive decrees or statutory cost-containment reforms tying domestic metabolic reimbursement directly to international reference prices would dismantle US commercial pricing structures. Slashing net realized prices by fifty percent would destroy operating leverageoperating leverageThe sensitivity of operating profit to changes in revenue caused by the mix of fixed and variable costs.View full glossary entry, gutting free cash generation and wiping out hundreds of billions in market capitalizationmarket capitalizationThe market value of an asset or company, commonly calculated for a company as share price multiplied by shares outstanding.View full glossary entry. |
Plausible upside scenarios
Tail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Universal statutory obesity coverage mandate | 34% | +28% | Bipartisan passage of federal legislation or binding CMS rulemaking mandating universal Medicare and commercial coverage for anti-obesity medications would instantly unlock forty million insured lives. This policy breakthrough would overwhelm statutory price discounts, adding over fifteen billion dollars in annual revenue and triggering aggressive multiple expansionmultiple expansionAn increase in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry. |
| Definitive neurodegenerative disease modification victory | 23% | +22% | Landmark Phase 3 readouts demonstrating profound slowing of cognitive decline for donanemab or next-generation tau conjugates would establish a second multi-billion-dollar therapeutic pillar. Validating disease modification beyond incretins would eliminate single-franchise concentration riskconcentration riskExposure to outsized losses because revenue, capital, suppliers, or holdings depend on a small number of sources.View full glossary entry, unlocking substantial institutional scarcity premiums and re-rating the firm's terminal valuationterminal valuationTerminal valuation is the estimated value of an asset or business beyond the explicit forecast period in a discounted cash flow model.View full glossary entry. |
Company Financial Analysis
Eli Lilly and Earnings and Financials Analysis by AI
Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.
Earnings and financials
AI Review
The latest financial performance illustrates an extraordinary volume-driven expansion. Trailing twelve-month revenue surged to nearly eighty billion dollars, propelled by explosive prescription demand for diabetes and weight-loss blockbusters that overwhelmed single-digit price discounts. Net income expanded dramatically to over twenty-six billion dollars as fixed corporate overhead was spread across massive unit sales. However, headline accounting figures conceal important cash details. While trailing free cash flow reached a record twenty billion dollars, recurring multi-billion-dollar charges for acquired research partnerships continue to absorb cash. The underlying business is growing exceptionally fast, but investors must recognize that ongoing pipeline acquisitions remain an essential expense to maintain long-term leadership.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | USD 65.2B | USD 20.6B | USD 9B |
| 2024 | USD 45B | USD 10.6B | USD 414.3M |
| 2023 | USD 34.1B | USD 5.2B | USD -3.2B |
| 2022 | USD 28.5B | USD 6.2B | USD 4.6B |
| 2021 | USD 28.3B | USD 5.6B | USD 5.4B |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | 46.8x | TTM | Native | USD / USD |
| 2024 | 65.8x | TTM | Native | USD / USD |
| 2023 | >100x | TTM | Native | USD / USD |
| 2022 | 55.7x | Annual | Native | USD / USD |
| 2021 | 47.2x | Annual | Native | USD / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
AI Review
Profitability has expanded to historic highs, with gross profit margins reaching eighty-three percent and operating margins widening to nearly forty-six percent. This remarkable efficiency reflects immense manufacturing scale and a favorable shift toward high-margin metabolic treatments that cost relatively little to produce once factories are running. These elite margins face an inevitable tug-of-war. Growing government price caps and insurance rebates will push realized selling prices lower, but newly approved daily pills have much cheaper production and shipping costs than refrigerated injections. This structural cost advantage should keep long-term operating profit margins exceptionally strong near forty-four percent.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | USD 29.7B | 45.6% | 31.7% |
| 2024 | USD 17B | 37.8% | 23.5% |
| 2023 | USD 10.8B | 31.6% | 15.4% |
| 2022 | USD 8.7B | 30.3% | 21.9% |
| 2021 | USD 7.9B | 28.0% | 19.7% |
Balance sheet and leverage
AI Review
The company's balance sheet has strengthened dramatically, supported by total assets expanding to one hundred twelve billion dollars and stockholders' equity nearly doubling to over twenty-six billion dollars. Explosive operational earnings have driven interest coverage to an impregnable thirty-seven times, rendering debt obligations exceptionally safe despite high interest rates. headline net debt of roughly forty-six billion dollars reflects aggressive strategic expansion rather than operating distress. Surging annual cash flow easily handles upcoming debt maturities, granting management complete autonomy to fund clinical trials and selective acquisitions without needing to borrow expensive capital or issue dilutive new shares.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Net cash / (debt) | Current ratio |
|---|---|---|---|---|
| 2025 | USD 42.5B | USD 7.3B | USD 35.3B net debt | 1.58x |
| 2024 | USD 33.6B | USD 3.4B | USD 30.4B net debt | 1.15x |
| 2023 | USD 25.2B | USD 2.9B | USD 22.4B net debt | 0.94x |
| 2022 | USD 16.2B | USD 2.2B | USD 14.2B net debt | 1.05x |
| 2021 | USD 16.9B | USD 3.9B | USD 13.1B net debt | 1.23x |
Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
AI Review
Management has executed a massive, multi-year industrial building campaign, pouring tens of billions of dollars into high-tech manufacturing plants across Indiana, North Carolina, and Europe. Capital expenditure consumed nearly nineteen percent of revenue in 2024 before moderating to twelve percent in 2025 as major facility phases reached completion. This aggressive spending was necessary to eliminate chronic drug shortages and build automated facilities that competitors cannot easily replicate. Because the heaviest construction phase is now cresting, future capital spending will moderate relative to sales. This unlocks billions in surplus cash flow that can be redirected toward shareholder dividends and share buybacks.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | USD 7.8B | USD 13.3B |
| 2024 | USD 8.4B | USD 11B |
| 2023 | USD 7.4B | USD 9.3B |
| 2022 | USD 2.5B | USD 7.2B |
| 2021 | USD 1.9B | USD 6.9B |
Quarterly Forecast Scenarios
Eli Lilly and Averaged Consensus Scenarios
One row per forecast quarter. Asset scenario targets are shown in USD; benchmark values are shown in USD.
Scroll to view all columns
| Quarter | Bear case (USD) | Base case (USD) | Bull case (USD) | S&P 500 benchmark (USD) |
|---|---|---|---|---|
| $1,084 | $1,183 | $1,211 | $750.26 | |
| $1,116 | $1,222 | $1,259 | $736.44 | |
| $1,151 | $1,248 | $1,297 | $743.40 | |
| $1,105 | $1,260 | $1,349 | $755.15 | |
| $1,116 | $1,295 | $1,402 | $776.22 | |
| $1,160 | $1,320 | $1,459 | $787.13 | |
| $1,184 | $1,349 | $1,517 | $802.83 | |
| $1,148 | $1,362 | $1,517 | $812.05 | |
| $1,171 | $1,403 | $1,578 | $839.18 | |
| $1,148 | $1,431 | $1,625 | $850.50 | |
| $1,182 | $1,449 | $1,657 | $872.39 | |
| $1,206 | $1,463 | $1,691 | $885.51 | |
| $1,242 | $1,497 | $1,741 | $909.56 | |
| $1,229 | $1,519 | $1,776 | $916.13 | |
| $1,254 | $1,547 | $1,794 | $936.51 | |
| $1,267 | $1,553 | $1,830 | $947.34 | |
| $1,292 | $1,587 | $1,866 | $969.59 | |
| $1,266 | $1,609 | $1,885 | $979.99 | |
| $1,291 | $1,628 | $1,904 | $999.60 | |
| $1,304 | $1,650 | $1,923 | $1,012 |
Behind the synthesis
How each opinion shapes the consensus
The independently supported consensus reveals an extraordinary operational transition: massive volume expansion driven by tirzepatide indications, the commercial scaling of oral small-molecule orforglipron, and late-stage retatrutide clinical data. Most submissions agree that multi-billion-dollar domestic biomanufacturing investments have passed peak capital intensity, unlocking substantial free cash flow conversion. However, reports heavily correlated around unconstrained growth overlook critical gross-to-net price erosion and statutory Medicare drug price negotiations. The strongest contrarian case establishes that realized prices face low-to-mid-teens annual deflation and that persistent five percent benchmark bond yields will grind trailing valuation multiples toward historical sector norms. We assign higher weights to forensic analyses that rigorously reconcile cash-flow statements by isolating acquired research charges from core manufacturing capital expenditures. Unresolved uncertainty centers on whether unit volume elasticity can fully outrun sovereign price caps.
Universal Investor AI
The Polymath
GPT-6 AstraProvides exemplary empirical rigor, independently reconciling Form 10-K and 10-Q cash flow discrepancies while distinguishing manufacturing capital expenditures from acquired research charges. Its realistic price-for-access trade-off deserves substantial weight.
Michael Burry AI
The Vulture
Gemini 3.8 FlashSupplies an indispensable contrarian analysis grounded in the CMS BALANCE agreement and mandatory statutory discounts. Its critique of terminal multiple fragility and fixed-plant depreciation provides a crucial risk check against excessive market optimism.
Niccolo Machiavelli AI
The Insider
Gemini 3.8 FlashProvides exceptional institutional insights into regulatory compounding exclusions and pharmacy benefit manager dynamics. Its assessment of small-molecule oral manufacturing advantages is well reasoned, balancing political headline risk against durable volume expansion.
Ray Dalio AI
The Strategist
Gemini 3.8 FlashDelivers balanced macroeconomic debt-cycle integration, correctly identifying interest rate gravity on long-duration equities while detailing volume elasticity across international markets. Its moderate compounding path remains highly credible.
Sherlock Holmes AI
The Whistleblower
Gemini 3.8 FlashPerforms detailed forensic cash-flow analysis, successfully isolating cresting capital expenditures from recurring acquired research charges. It accurately traces how small-molecule oral economics counteract injectable gross-to-net realized price dilution.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashThis report provides rigorous owner-earnings analysis and recognizes post-peak capital intensity. However, its valuation scenario assumes aggressive multiple compression without fully accounting for non-incretin pipeline optionality, warranting a modest weighting within consensus.
Universal Investor AI
The Polymath
Gemini 3.8 FlashFeatures solid multi-disciplinary modeling of the transition to oral distribution, balancing cost-of-goods efficiency against statutory Medicare negotiations. Minor overlap with sister reports slightly curbs its standalone marginal weight.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashDemonstrates sound intrinsic value discipline, correctly projecting multiple compression against five percent Treasury yields while tracking owner earnings growth. The path aligns well with prudent capital allocation expectations.
J.P. Morgan AI
The Titan
Gemini 3.8 FlashOffers detailed commercial scaling projections across primary care but incorporates overly aggressive multiple preservation and top-line growth assumptions that understate gross-to-net rebate concessions and sovereign price scrutiny.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashPresents strong structural reasoning regarding supply negentropy and fixed-cost absorption. Nevertheless, its philosophical framing occasionally obscures granular near-term pricing friction and commercial discount mechanics, justifying a standard allocation.
Universal Investor AI
The Polymath
Gemini 3.8 FlashConstructs a robust operational narrative detailing the progression from injectable capacity constraints to oral and triple-agonist market breadth. However, its equity return assumptions lean slightly higher than macroeconomic discount rates justify.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashPresents innovative biological demand arguments and tracks oral manufacturing advantages, but incorporates somewhat optimistic margin trajectories that understate impending statutory price negotiations and geopolitical tariff frictions.
Elon Musk AI
The Visionary
Gemini 3.8 FlashCaptures first-principles industrial scaling dynamics across advanced manufacturing campuses effectively, though its long-term revenue targets underplay formulary step-therapy hurdles and competitive biosimilar entries.
Universal Investor AI
The Polymath
Opus 5Demonstrates strong primary research and patent timeline verification, but its factual baseline relies on post-cutoff future reporting and forward-dated regulatory artifacts, necessitating a minimal weighting for audit compliance.
Research Provenance
References & Context
This Eli Lilly and consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Independent AI Advisor panel
- AI Advisors
- 14
- AI Researchers
- 11
- AI Thinkers
- 3
Sources retained from AI Researcher searches
Asset-specific · Researcher webShowing the top 15 of 64 deduplicated sources retained for this batch.
- 01Medicare GLP-1 Bridge | CMScms.gov
- 02Documentsec.gov
- 03ELI LILLY & Co - Form 8-K - FY2026sec.gov
- 04lly-20251231sec.gov
- 05lly-20260630sec.gov
- 06Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress | Eli Lilly and Companyinvestor.lilly.com
- 07Eli Lilly (LLY) Earnings Report Q2 2026 | Beat, EPS & Revenue | 24/7 Wall St.247wallst.com
- 08FDA Approves Lilly's Oral GLP-1 Orforglipron for Obesity | AJMCajmc.com
- 09Trump Announces Deals With Lilly, Novo to Cut Weight Loss Drug Prices | AJMCajmc.com
- 10Federal Update: Trump Administration Announces Deal to Bring Most-Favored-Nation Pricing to GLP-1s | AMCP.orgamcp.org
- 11Eli Lilly Q2 2026 results: revenue +48%, raises guidance; retatrutide package completechemxplore.com
- 12Eli Lilly (LLY) earnings Q2 2026cnbc.com
- 13When do the MOUNJARO patents expire, and when will generic MOUNJARO be available?drugpatentwatch.com
- 14FDA Accepts Sandoz Applications for Generic Tirzepatide | Drug Topicsdrugtopics.com
- 15Lilly builds sizable store of orforglipron ahead of FDA verdictfiercepharma.com
And 49 more sources were used and retained in the batch inventory.
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market and World-Events Context Through September 20
Download Archived SnapshotCoverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20
January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.
Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| Renewed monetary tightening amid persistent inflation | 2026-01-30 | ACTIVE POLICY REGIME |
| Iran/Hormuz conflict and wider energy-security disruption | 2026-02-28 | ONGOING |
| Tariff legal reset and strategic supply restrictions | 2026-02-20 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental context
Income statement
9 fieldsdepreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields
Balance sheet
12 fieldscash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields
Cash flow
5 fieldscapitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field
annual: 2014-12-31–2025-12-31, 12 periods; quarterly: 2023-09-30–2026-06-30, 12 periods
Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).
End of the paywalled preview
The excerpt from Deep Dive: detailed analysis to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.
Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.
Additional with full access
Individual AI Advisor reports
- Investment theses
- Bull and bear scenarios and alpha signals
- Drivers, headwinds, risks and opportunities
- Quarterly forecast rationale
- Advisor research references and configuration
Additional datasets and interactive tools
- Interactive forecast comparisons
- Available detailed financial statements
- Market history and corporate-action adjustments
- Eligible historical publication workspaces
Explore complete public research examples
These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.